| Adeona Pharmaceuticals announced that it has received Institutional Review Board approval to initiate a 60 patient, randomized, double-blind, placebo-controlled clinical trial of its patent pending Zinthionein ZC-GS150 in an Alzheimer's disease and mild cognitive impairment patient group. The clinical trial, titled "CopperProof 2," will test, for the first time, the effects of a novel gastro-retentive, sustained release zinc/cysteine combination tablet on the amelioration of sub-clinical zinc deficiency, and elevated percentage serum free copper, associated with Alzheimer's Disease. :theflyonthewall.com |
